The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease
Open accessAbstract
This study conducted exploratory analyses of the effects of BIIB080, a MAPT (microtubule-associated protein tau)-targeting antisense oligonucleotide, in participants with mild Alzheimer’s disease. A multicenter, randomized, double-blind, phase 1b trial was conducted as a placebo-controlled, multiple-ascending dose (MAD) study followed by an open-label, long-term extension (LTE). During the MAD study, participants were randomized and received either intrathecal placebo or BIIB080 10 mg (n = 6), 30 mg (n = 6) or 60 mg (n = 9) every 4 weeks or 115 mg (n = 13) every 12 weeks (Q12W). During the LTE, participants received high-dose BIIB080 (60 mg (n = 7) or 115 mg (n = 9) Q12W). BIIB080 was generally well tolerated. Here we present findings from exploratory analyses, which showed a consistent trend of slowed decline on cognitive, functional and global measures favoring BIIB080 high-dose groups at the end of both study periods. This favorable trend is supported by reported reductions from baseline in brain neurofibrillary tangles measured with tau positron emission tomography. Trial registration: ClinicalTrials.gov identifier: NCT03186989 . This exploratory analysis of a phase 1b study evaluating BIIB080, a MAPT-targeting antisense oligonucleotide, in mild Alzheimer’s disease indicates favorable trends of high-dose BIIB080 in slowing cognitive and functional decline, supporting the need for future trials evaluating clinical efficacy of BIIB080 in mild Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Edwards, A. L., Collins, J. A., Junge, C., Kordasiewicz, H., Mignon, L., Wu, S., Li, Y., Lin, L., DuBois, J., Hutchison, R. M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3861 · Cited by 113
Self-citation
Flagged first, then by citations
Research works printed but not linked: 22
- Coomans, E. M. et al. A head-to-head comparison between plasma ptau181 and tau PET along the Alzheimer’s disease continuum. J. Nucl. Med. 64, 437–443 (2023). · DOI
- Mummery, C. J. et al. Tau-targeting antisense oligonucleotide MAPTRX in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nat. Med. 29, 1437–1447 (2023). · DOI · Paper page
- Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 9, 197–210 (2022). · DOI · Paper page
- Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527 (2023). · DOI · Paper page
- Corsi, A. et al. Tau isoforms: gaining insight into MAPT alternative splicing. Int. J. Mol. Sci. 23, 15383 (2022). · DOI
- Yang, J. et al. Complicated role of post-translational modification and protease-cleaved fragments of tau in Alzheimer’s disease and other tauopathies. Mol. Neurobiol. 61, 4712–4731 (2024). · DOI
- Malpetti, M., Joie, R. & Rabinovici, G. D. Tau beats amyloid in predicting brain atrophy in Alzheimer disease: implications for prognosis and clinical trials. J. Nucl. Med. 63, 830–832 (2022). · DOI · Paper page
- van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023). · DOI · Paper page
- Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 46, 399–424 (2011). · DOI · Paper page
- O’Bryant, S. E. et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s Research Consortium study. Arch. Neurol. 65, 1091–1095 (2008). · DOI
- DeVos, S. L. et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33, 12887–12897 (2013). · DOI · Paper page
- Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7, 270–279 (2011). · DOI · Paper page
- Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975). · DOI · Paper page
- Kennedy, R. E. et al. Using baseline cognitive severity for enriching Alzheimer’s disease clinical trials: how does Mini-Mental State Examination predict rate of change? Alzheimers Dement. (N Y) 1, 46–52 (2015). · DOI
- Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412–2414 (1993). · DOI · Paper page
- Marshall, G. A. et al. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement. 7, 300–308 (2011). · DOI
- Brown, P. J. et al. Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch. Gen. Psychiatry 68, 617–626 (2011). · DOI · Paper page
- Pfeffer, R. I. et al. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323–329 (1982). · DOI
- Randolph, C. et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 20, 310–319 (1998). · DOI · Paper page
- Duff, K. et al. Diagnostic accuracy of the RBANS in mild cognitive impairment: limitations on assessing milder impairments. Arch. Clin. Neuropsychol. 25, 429–441 (2010). · DOI
- Randolph, C. RBANS: Repeatable Battery for the Assessment of Neuropsychological Status: Manual (The Psychological Corporation, 1998). · DOI
- Shulman, M. et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease. Nat. Aging 3, 1591–1601 (2023). · DOI
Metadata
- Authors
- Shulman, M., Wu, S., Ziogas, N., Edwards, A., Collins, J., Lin, L., Tien, I., Curiale, G., Li, Y., Mummery, C., Lane, R., Junge, C., Beaver, J., Tian, Y., Landen, J., Bullain, S., & Gallagher, D.
- Affiliations
- Biogen (United States) (US)
- National Hospital for Neurology and Neurosurgery (GB)
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Shulman, Melanie
- ORCID
- Venue
- Nature Aging
- Published
- 2026-02-11
- Volume
- 6
- Issue
- 2
- Pages
- 445-453
- ISSN
- 2662-8465 (ISSN-L)
- PMC
- PMC12920120
- OpenAlex
- W7128599889
- Cited by
- 11
- References
- 5
- Citations by year
- 2026: 11
- FWCI
- 40.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Aging (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Funders
- Ionis and Biogen Inc.
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- MAPT, mild Alzheimer's disease, intrathecal drug delivery, cognitive decline, functional decline, neurofibrillary tangles, tau PET, dose escalation, long-term extension study
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles, Male, Oligonucleotides, Oligonucleotides, Antisense, tau Proteins, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
